Xagenic’s Rapid Molecular Platform Gets Series B Boost
With a new $20 million bankroll, Xagenic Inc, Toronto, says it’s on the way to developing a rapid, point-of-care molecular diagnostics platform suitable for use in physician offices and clinics.
Read More